Bottom line
How much do PPH and FPHAX overlap?
41% of their top holdings overlap by weight. 9 securities appear in both funds' top 25, making up 46.5% of PPH's assets and 64.4% of FPHAX's. They share a meaningful core but differ in the rest of the portfolio.
FPHAX holds far more positions (57 vs 26), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings PPH and FPHAX have in common
| Holding | % of PPH | % of FPHAX | Overlap |
|---|---|---|---|
| Eli Lilly & Co | 20.23% | 28.78% | 20.23% |
| Merck & Co Inc | 9.85% | 4.74% | 4.74% |
| Gsk Plc | 4.42% | 8.17% | 4.42% |
| Johnson & Johnson | 4.35% | 3.77% | 3.77% |
| AstraZeneca PLC | 4.33% | 4.22% | 4.22% |
| Viatris Inc | 1.10% | 5.45% | 1.10% |
| Jazz Pharmaceuticals PLC | 1.08% | 4.09% | 1.08% |
| Axsome Therapeutics Inc | 0.77% | 1.08% | 0.77% |
| Elanco Animal Health Inc | 0.35% | 4.15% | 0.35% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / May 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PPH
- Novartis AG — 10.63%
- Novo Nordisk A/S — 5.37%
- AbbVie Inc — 4.57%
- Pfizer Inc — 4.51%
- Bristol-Myers Squibb Co — 4.47%
- McKesson Corp — 4.12%
- Sanofi SA — 4.00%
- Cencora Inc — 3.36%
- Haleon PLC — 3.09%
- Teva Pharmaceutical Industries Ltd — 3.06%
- Takeda Pharmaceutical Co Ltd — 2.87%
- Zoetis Inc — 2.10%
- Corcept Therapeutics Inc — 0.50%
- State Street Global Advisors — 0.28%
- Organon & Co — 0.23%
Only in FPHAX
- Ucb Sa — 5.09%
- Roche Holding Ag — 4.54%
- Legend Biotech Corp — 4.53%
- Gilead Sciences Inc — 3.97%
- Royalty Pharma Plc — 2.67%
- Fidelity Revere Street Trust — 2.44%
- Moderna Inc — 1.57%
- Intellia Therapeutics Inc — 1.19%
- Beam Therapeutics Inc — 1.10%
- Biontech Se — 1.04%
- Xenon Pharmaceuticals Inc — 0.82%
- Ocular Therapeutix Inc — 0.80%
- Idexx Laboratories Inc — 0.61%
- Swedish Orphan Biovitrum Ab — 0.54%
- Ptc Therapeutics Inc — 0.54%
Asset mix
| Asset type | PPH | FPHAX |
|---|---|---|
| Stocks | 99.5% | 98.7% |
| Cash & short-term funds | 0.3% | 2.6% |
| Preferred stock | — | 0.7% |
| Bonds | — | 0.1% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / May 31, 2026)
Country mix
| Country | PPH | FPHAX |
|---|---|---|
| US | 60.8% | 64.8% |
| GB | 11.8% | 15.1% |
| CH | 10.6% | 4.5% |
| DK | 5.4% | 0.3% |
| BE | — | 5.3% |
| KY | — | 4.5% |
| IE | 1.1% | 4.1% |
| FR | 4.0% | — |
Source: SEC Form N-PORT (periods Jun 30, 2026 / May 31, 2026)
Check another pair
FAQ
How much do PPH and FPHAX overlap?
What stocks do PPH and FPHAX have in common?
Should I own both PPH and FPHAX?
Which holds more stocks, PPH or FPHAX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.